It is considered appropriate to use Pegfilgrastim (Neulasta®) in the following conditions

To decrease the incidence of infection as manifested by febrile neutropenia in patients with non-myeloid malignancies receiving a myelosuppressive chemotherapy regimen associated with a clinically significant incidence of febrile neutropenia in an outpatient setting.

Patients who would have been expected to receive greater than 7 days of filgrastim (G-CSF) in an outpatient setting.

It is considered inappropriate to use Pegfilgrastim (Neulasta®) in the following conditions:

In an inpatient setting

It is recommend not to administer pegfilgrastim within 24 hours after the administration of cytotoxic chemotherapy

3. Within 14 days prior to the administration of cytotoxic chemotherapy.

In infants, children, and adolescents weighing less than 45 kg

For any indication unapproved by the FDA. The following table demonstrates the FDA-approved indications for pegfilgrastim vs. those for filgrastim

For stimulation of stem cell production prior to bone marrow transplantation.